|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Change in model for end-stage liver disease score at two weeks,as an indicator of mortality or liver transplantation at 60 days in acute-on-chronic liver failure显示文摘Background:Acute-on-chronic liver failure(ACLF)is characterised by a sudden deterioration of underlying chronic liver disease,resulting in increased rates of mortality and liver transplantation.Early prognostication can benefit optimal allocation of resources.Methods:ACLF was defined as per the disease criteria of the Asian Pacific Association for the Study of the Liver.Inpatient discharge summaries from between January 2001 and April 2013 were reviewed.The primary outcome was mortality or liver transplantation within 60 days from onset of ACLF.Absolute‘model for end-stage liver disease’(MELD)score and change in MELD at Weeks 1,2 and 4 were reviewed in order to identify the earliest point for prediction of mortality or liver transplantation.Results:Clinical data were collected on 53 subjects who fulfilled the inclusion and exclusion criteria.At 60 days from presentation,20 patients(37.7%)died and 4(7.5%)underwent liver transplantation.Increased MELD of-2 after 2 weeks was 75.0%sensitive and 75.9%specific for predicting mortality or liver transplantation.If the MELD score did not increase at 2 weeks,predictive chance of survival was 93.8%over the next 60 days.MELD change at 1 week showed poor sensitivity and specificity.Change at 4 weeks was too late for intervention.Conclusion:Change in MELD score at 2 weeks provides an early opportunity for prognostication in ACLF.A MELD score that does not deteriorate by Week 2 would predict 93.8%chance of survival for the next 60 days.This finding warrants further validation in larger cohort studies. | Rajneesh Kumar Thinesh Lee Krishnamoorthy Hiang Keat Tan Hock Foong Lui Wan Cheng Chow | 2015 | Gastroenterology Report2015，3，2： | 2 |
| 2 | 对于非酒精性脂肪肝病的认识——基于亚洲人群的研究显示文摘背景和目的:非酒性脂肪肝病(NAFLD)是最常见的慢性肝病,同时也是代谢综合征的一项危险因素。NAFLD在全球范围内的患病率基于地域差异在5%~30%不等。尽管流行病学资料显示代谢相关性疾病的患病率在新加坡呈快速增长,但对于该地区NAFLD的数据却十分有限。本研究旨在了解新加坡NAFLD的患病率及公众对该病的认识。方法:本研究是一项横断面观察研究,旨在评估NAFLD患者的人口统计学、人体测量学及临床资料,研究对象来自于一项胃肠公众论坛的参会者。NAFLD的诊断基于超声学标准;代谢综合征的诊断则基于国际糖尿病联盟的指南。通过自行设计的调查问卷来了解大家对NAFLD这种疾病的看法。结果:共有227名研究对象纳入研究,其中40%被诊断为NAFLD。相对于那些非NAFLD人群,NAFLD者男性居多,年龄更大,体质指数更高,腰围更宽,患代谢性综合征的比例更高(均P<0.05)。尽管有71.2%的研究对象之前听说过NAFLD,但其中仅25.4%认为自己具有NAFLD的风险。有无代谢风险因素者对NAFLD的认识差不多(P>0.05)。值得注意的是,75.6%的具有代谢危险因素者,并不认为自己存在NAFLD风险。结论:我们的研究显示NAFLD在新加坡具有较高的患病率,包括在那些非肥胖人群中。考虑到人们对NAFLD的发生风险认识不足,有必要加强公众教育,以提高人们对NAFLD的认识。 | George B.B.Goh Clarence Kwan Sze Ying Lim Nanda KK Venkatanarasimha Rafidah Abu-Bakar Thinesh L Krishnamoorthy Hang Hock Shim Kiang Hiong Tay Wan Cheng Chow | 2016 | Gastroenterology Report2016，4，2： | 1 |
| 3 | Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009显示文摘 | Donald Poon Benjamin O Anderson Li-Tzong Chen Koichi Tanaka Wan Yee Lau Eric Van Cutsem Harjit Singh Wan Cheng Chow London Lucien Ooi Pierce Chow Maung Win Khin Wen Hsin Koo | 2009 | Lancet Oncology2009，，11： | 1 |
| 4 | Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009显示文摘 | Donald Poon Benjamin O Anderson Li-Tzong Chen Koichi Tanaka Wan Yee Lau Eric Van Cutsem Harjit Singh Wan Cheng Chow London Lucien Ooi Pierce Chow Maung Win Khin Wen Hsin Koo | 2009 | Lancet Oncology2009，，11： | 1 |
| 5 | Reduction of HBV replication prolongs the early immunological response to IFNα therapy显示文摘 | Anthony T. Tan Long Truong Hoang Daniel Chin Erik Rasmussen Uri Lopatin Stefan Hart Hans Bitter Tom Chu Lore Gruenbaum Palani Ravindran Hua Zhong Ed Gane Seng Gee Lim Wan Cheng Chow Pei-Jer Chen Rosemary Petric Antonio Bertoletti Martin Lloyd Hibberd | 2014 | Journal of Hepatology2014，，1： | 1 |
| 6 | Real world experience with Pegylated Interferon and ribavirin in Hepatitis C Genotype 1 population with favourable IL28B polymorphism显示文摘背景与目的:丙型肝炎(HCV)的传统治疗是应用聚乙二醇干扰素(FEG-IFN)和病毒唑,但副作用明显。IL28B基因多态性可以预测治疗反应,CC基因型者效果更好。ITPA基因缺失能对治疗引起的临床贫血起到保护作用。本研究目的是检测接受FEG-IFN和病毒唑治疗的1型HCV患者中IL28B基因多态性和ITPA基因突变情况,并分析其与持续病毒学应答(SVR)的相关性。方法:通过病历记录查询过去10年所有接受FEG-IFN和病毒唑治疗的1型HCV患者,通过信函邀请其参加本次研究。采集患者血液标本用以IL28B和ITPA基因检测。从病历记录中提取治疗反应、贫血发生及治疗中断情况。结果:共有61例1型HCV患者接受了FEG-IFN和病毒唑治疗,其中42例同意参加本次研究。治疗时平均年龄为(45.6±12.9)岁,男性患者占83.3%。33例(78.6%)检测为IL28B CC基因型,其中25例(75.8%)获得SVR,而9例非CC基因型患者中仅3例(33.3%)获得SVR(P=0.041)。11例患者检测为ITPA AC基因型,30例为CC基因型。ITPA AC与CC基因型患者的临床贫血发生率的差异无统计学意义(45.5%vs.63.3%,P=0.302)。即便在出现临床贫血的患者中,仍有70.8%最终获得了SVR。治疗中断对SVR亦无影响。结论:对于IL28B CC基因型的1型HCV患者,在考虑新的治疗选择前,应告知其FEG-IFN和病毒唑具有良好的治疗效果。 | Victoria Ekstrom Rajneesh Kumar Yi Zhao Mei Ling Yee Cynthia Sung Dorothy Toh Poh Yen Loh Jessica Tan Eng Kiong Teo Wan Cheng Chow | 2017 | Gastroenterology Report2017，5，3： | 0 |
| 7 | The Hong Kong consensus recommendations on the diagnosis and management of pancreatic cystic lesions显示文摘Background:The finding of pancreatic cystic lesions(PCL)on incidental imaging is becoming increasingly common.International studies report a prevalence of 2.2-44.7%depending on the population,imaging modality and indication for imaging,and the prevalence increases with age.Patients with PCL are at risk of developing pancreatic cancer,a disease with a poor prognosis.This publication summarizes recommendations for the diagnosis and management of PCL and post-operative pancreatic exocrine insufficiency(PEI)from a group of local specialists.Methods:Clinical evidence was consolidated from narrative reviews and consensus statements formulated during two online meetings in March 2022.The expert panel included gastroenterologists,hepatobiliary surgeons,oncologists,radiologists,and endocrinologists.Results:Patients with PCL require careful investigation and follow-up due to the risk of malignant transformation of these lesions.They should undergo clinical investigation and pancreas-specific imaging to classify lesions and understand the risk profile of the patient.Where indicated,patients should undergo pancreatectomy to excise PCL.Following pancreatectomy,patients are at risk of PEI,leading to gastrointestinal dysfunction and malnutrition.Therefore,such patients should be monitored for symptoms of PEI,and promptly treated with pancreatic enzyme replacement therapy(PERT).Patients with poor response to PERT may require increases in dose,addition of a proton pump inhibitor,and/or further investigation,including tests for pancreatic function.Patients are also at risk of new-onset diabetes mellitus after pancreatectomy;they should be screened and treated with insulin if indicated.Conclusions:These statements are an accurate summary of our approach to the diagnosis and management of patients with PCL and will be of assistance to clinicians treating these patients in a similar clinical landscape. | Tan-To Cheung Yuk Tong Lee Raymond Shing-Yan Tang Wong Hoi She Kai Chi Cheng Chin Cheung Cheung Keith Wan Hang Chiu Kenneth Siu Ho Chok Wing Sun Chow Tak Wing Lai Wai-Kay Seto Thomas Yau | 2023 | Hepatobiliary Surgery and Nutrition2023，12，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员